Jesús Delgado‐Calle
Assistant Professor
Also affiliated: Universidad Autónoma de Tlaxcala (2004); Indiana University Health (2017–2020); Universidad de Cantabria (2011–2017); United States Department of Veterans Affairs (2016); University of Indianapolis (2016–2019); Marqués de Valdecilla University Hospital (2011–2017); Indiana Cancer Consortium (2017); Fundación Marques de Valdecilla (2011–2013); Richard L. Roudebush VA Medical Center (2014–2020); Instituto de Investigación Marqués de Valdecilla (2012–2017); Winthrop Rockefeller Foundation (2020–2025); Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (2014); University School (2013–2017); Institute of Cell Biology and Neurobiology (2019); Indiana Hemophilia and Thrombosis Center (2017); Indiana University School of Medicine (2013–2020); University of Córdoba (2022); Indiana University – Purdue University Indianapolis (2014–2020); Indiana University (2013–2017); Universidad Nacional Autónoma de México (2013)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Jesús Delgado‐Calle's research focuses on the role of osteocytes in bone health and disease, particularly in the context of multiple myeloma. He has received two NIH/National Cancer Institute grants totaling $1,373,203 to investigate the contribution of osteocytes to the musculoskeletal effects of multiple myeloma and to develop bone-targeted therapies for multiple myeloma patients. His work also explores the impact of cancer metastasis on bone, including the identification of senescent osteocytes that trigger bone destruction in breast cancer metastasis.
Delgado‐Calle's publications address the signaling functions of osteocytes, the mechanisms of bone destruction in multiple myeloma, and the involvement of Notch signaling pathways. He has also investigated the role of extrachromosomal circular DNA in biological processes. His research network includes extensive collaborations with colleagues at the University of Arkansas for Medical Sciences, such as Hayley M. Sabol, Teresita Bellido, Sharmin Khan, and Aric Anloague.
With an h-index of 30 and over 3,590 citations across 211 publications, Delgado‐Calle is recognized as a highly cited researcher. He actively maintains a laboratory website to share his work and findings.
Metrics
- h-index: 31
- Publications: 211
- Citations: 3,651
Selected Publications
-
An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025)
-
An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates (2025)
-
Ex Vivo Model Systems of Cancer-Bone Cell Interactions (2025)
-
2D and 3D In Vitro Co-culture for Cancer and Bone Cell Interaction Studies (2025)
-
Abstract 5099: Notch inhibition as a therapeutic approach to eliminate dormant cancer cells in multiple myeloma (2025)
-
Paracrine activity of Smurf1-silenced mesenchymal stem cells enhances bone regeneration and reduces bone loss in postmenopausal osteoporosis (2025)
-
Unlocking acid ceramidase: a new weapon against proteasome chemoresistance in myeloma (2025)
Federal Grants 2 $1,373,203 total
Bone-Targeted Therapies to Improve Bone Health and Prevent Relapse in Multiple Myeloma
Contribution of osteocytes to the musculoskeletal effects of Multiple Myeloma
Collaboration Network
Top Collaborators
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- The multifunctional role of Notch signaling in multiple myeloma
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
Showing 5 of 12 shared publications
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
Showing 5 of 8 shared publications
- CReSIL: accurate identification of extrachromosomal circular DNA from long-read sequences
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
Showing 5 of 8 shared publications
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
Showing 5 of 7 shared publications
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- Osteocytes and Paget’s Disease of Bone
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
Showing 5 of 7 shared publications
- The osteocyte as a signaling cell
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Wnt/β-catenin Signaling Controls Maxillofacial Hyperostosis
Showing 5 of 7 shared publications
- Osteocytes: New Kids on the Block for Cancer in Bone Therapy
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
Showing 5 of 7 shared publications
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma
- Abstract 5672: Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
- Senolytics deplete senescent osteocytes and improve bone health in metastatic breast cancer
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
- Senolytics deplete senescent osteocytes and improve bone health in metastatic breast cancer
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- Abstract 5672: Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- Abstract 5672: Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma
- Abstract 5672: Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- Abstract 5672: Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
Similar Researchers
Based on overlapping research topics